[go: up one dir, main page]

PE27899A1 - Formulacion de particulas revestidas - Google Patents

Formulacion de particulas revestidas

Info

Publication number
PE27899A1
PE27899A1 PE1997000854A PE00085497A PE27899A1 PE 27899 A1 PE27899 A1 PE 27899A1 PE 1997000854 A PE1997000854 A PE 1997000854A PE 00085497 A PE00085497 A PE 00085497A PE 27899 A1 PE27899 A1 PE 27899A1
Authority
PE
Peru
Prior art keywords
formulation
preference
methyl
polymer
wax
Prior art date
Application number
PE1997000854A
Other languages
English (en)
Inventor
Tommy Clifford Morris
Hans Joerg Lange
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE27899A1 publication Critical patent/PE27899A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UNA FORMULACION ORAL SOLIDA EN GRANULOS O TABLETAS QUE NO REQUIEREN REVESTIMIENTO INTERIOR, QUE COMPRENDE: 2-METIL-4-(4-METIL-1-PIPERAZINIL)-1OH-TIENO[2,3-b][1,5] BENZODIACEPINA (OLANZAPINA) REVESTIDA CON UN POLIMERO; DE PREFERENCIA SE UTILIZA LA FORMA ANHIDRA MAS ESTABLE O LA FORMA (II) DE OLANZAPINA CARACTERIZADO SEGUN SUS ESPACIOS INTERPLANARES (d) MEDIDOS EN EL DIFRACTOMETRO DE RAYOS X : 10,2689 8,577 7,4721 7,125 6,1425 6,071 5,4849 5,2181 5,1251 4,9874 4,7665 4,7158 4,4787 4,3307 4,2294 4,141 3,9873 3,7206 3,5645 3,5366 3,3828 3,2516 3,134 3,0848 3,0638 3,0111 2,8739 2,8102 2,7217 2,6432 2,6007; EL POLIMERO SE SELECCIONA DE ALCOHOL CETILICO, CERA DE ESTERES CETILICOS, CERA DE CARNAUBA, GOMA, CERA DE ABEJAS, ESTEARATO DE MAGNESIO, ENTRE OTROS, DE PREFERENCIA ES HIDROXIPROPILMETILCELULOSA LIBRE DE POLIETILENGLICOL. ESTA FORMULACION PRESENTA UN COLOR Y ASPECTO PERSISTENTE, SIENDO UTIL EN EL TRATAMIENTO PSICOTICO
PE1997000854A 1996-09-24 1997-09-23 Formulacion de particulas revestidas PE27899A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2663396P 1996-09-24 1996-09-24

Publications (1)

Publication Number Publication Date
PE27899A1 true PE27899A1 (es) 1999-03-12

Family

ID=21832952

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000854A PE27899A1 (es) 1996-09-24 1997-09-23 Formulacion de particulas revestidas

Country Status (21)

Country Link
US (1) US20010020032A1 (es)
EP (1) EP0830858A1 (es)
JP (1) JP2001501207A (es)
KR (1) KR20000048540A (es)
CN (1) CN1230883A (es)
AR (1) AR009802A1 (es)
AU (1) AU719788B2 (es)
BR (1) BR9713215A (es)
CA (1) CA2266448A1 (es)
CO (1) CO4910139A1 (es)
CZ (1) CZ98899A3 (es)
EA (1) EA001610B1 (es)
HU (1) HUP9904065A3 (es)
ID (1) ID21762A (es)
IL (1) IL128845A0 (es)
NO (1) NO991405L (es)
PE (1) PE27899A1 (es)
PL (1) PL332503A1 (es)
TR (1) TR199900651T2 (es)
WO (1) WO1998013027A1 (es)
ZA (1) ZA978517B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
TWI275394B (en) * 2000-01-26 2007-03-11 Asahi Chemical Corp Mizoribin tablet improved with color tone change
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SI21303A (sl) * 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Farmacevtska formulacija olanzapina
CA2510319A1 (en) 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
JP4808612B2 (ja) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
WO2005009407A2 (en) * 2003-07-29 2005-02-03 Ranbaxy Laboratories Limited Oral pharmaceutical formulations of olanzapine
DE112005000641T5 (de) 2004-09-06 2007-09-06 Shasun Chemicals and Drugs Ltd., Chennai Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
ES2279715B1 (es) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
DE602006014030D1 (de) * 2006-07-05 2010-06-10 Bilim Ilac Sanayii Ve Ticaret Stabile olanzapin-formulierung mit antioxidantien
AR063043A1 (es) * 2006-09-29 2008-12-23 Synthon Bv Composicion farmaceutica de olanzapina
SI2563763T1 (sl) * 2010-04-30 2015-03-31 Bristol-Myers Squibb Company Farmacevtski sestavki, ki obsegajo N-(4-(2-amino-3-kloropiridin-4-iloksi)-3-fluorofenil)-4-etoksi-L-(4- fluorofenil)-2-okso-1,2-dihidropiridin-3-karboksamid
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
KR102069473B1 (ko) 2013-03-21 2020-01-22 유프락시아 파마수티컬스 유에스에이 엘엘씨 주입가능한 서방성 방출 조성물 및 관절 내 염증 및 이와 관련된 통증을 치료하기 위해 이를 사용하는 방법
TR201808237T4 (tr) 2015-10-27 2018-07-23 Eupraxia Pharmaceuticals Inc Lokal anestetiklerin sürekli salım formülasyonları.
CN107007559B (zh) * 2017-04-21 2020-05-15 浙江京新药业股份有限公司 一种稳定的口服药物组合物及其制备方法
JP2021505595A (ja) 2017-12-05 2021-02-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 結晶形およびその製造方法
KR20200110648A (ko) 2017-12-05 2020-09-24 선오비온 파마슈티컬스 인코포레이티드 비라세믹 혼합물 및 이의 용도
BR112021024380A2 (pt) 2019-06-04 2022-04-19 Sunovion Pharmaceuticals Inc Formulações de liberação modificadas e usos das mesmas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
NZ247703A (en) * 1992-05-29 1995-07-26 Lilly Industries Ltd Thienobenzdiazepine derivatives and medicaments thereof
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina

Also Published As

Publication number Publication date
PL332503A1 (en) 1999-09-13
CN1230883A (zh) 1999-10-06
US20010020032A1 (en) 2001-09-06
CZ98899A3 (cs) 1999-12-15
JP2001501207A (ja) 2001-01-30
IL128845A0 (en) 2000-01-31
CO4910139A1 (es) 2000-04-24
NO991405D0 (no) 1999-03-23
EA199900331A1 (ru) 2000-04-24
EP0830858A1 (en) 1998-03-25
AU719788B2 (en) 2000-05-18
EA001610B1 (ru) 2001-06-25
ZA978517B (en) 1999-03-23
KR20000048540A (ko) 2000-07-25
WO1998013027A1 (en) 1998-04-02
AU4423097A (en) 1998-04-17
NO991405L (no) 1999-03-23
BR9713215A (pt) 2000-04-04
TR199900651T2 (xx) 1999-07-21
HUP9904065A2 (hu) 2000-04-28
ID21762A (id) 1999-07-22
HUP9904065A3 (en) 2001-10-29
CA2266448A1 (en) 1998-04-02
AR009802A1 (es) 2000-05-03

Similar Documents

Publication Publication Date Title
PE27899A1 (es) Formulacion de particulas revestidas
CA2059316A1 (en) Air freshener device with visual signal means
HUP9800410A2 (hu) Szájon át adható 2-metil-tieno-benzodiazepin-készítmény
PT841956E (pt) Artigo absorvente descartavel tendo uma camada superior com uma locao contendo um emoliente e um agente imobilizante de poliester de poliol
BR0113067A (pt) Forma de dosagem de drogas à base de hidrogel
HK1045708A1 (zh) 能够形成用於成型加工的碱溶性潤滑膜基材的塗料組合物及其用途
DE69637669D1 (de) Myogene differenzierung menschlicher mesenchymaler stammzellen
ID24479A (id) Eter-eter diaril dan proses pembuatannya serta komposisi-komposisi herbisida serta pengering yang mengandung eter diaril
AR003908A1 (es) Tableta de liberacion controlada
PE110298A1 (es) Dihidrato d de olanzapina
KR20040019070A (ko) 겔 공기 청정 장치
HUP9601161A2 (en) Use of retinoids in cosmetic compositions or for the manufacture of pharmaceutical compositions
BR9704559A (pt) Película com camada de substrato contendo agente de antibloqueio
BR9508559A (pt) Processo de descontaminação de um ambiente processo de esterlização de superfídie fria processo de desinfecção composiçao superficie sólida substancialmente não-porosa e superfície sólida revestida com um resíduo
ZA90778B (en) Extended release gemfibrozil composition
BR0006072A (pt) Composição impermeável à água, processos e aplicações da mesma
ZA987426B (en) Air freshener dispenser device with taper candle feature
CA2264626A1 (en) Pharmaceutical composition containing lornoxicam and a disodium salt of edta
NO982700L (no) Mikrobiell 11<alfa>-hydroksylering av steroider
AU2807197A (en) Compounds inhibiting the association of the pdgf receptor and phosphatidylinositol 3-kinase and their use
FR2745500B1 (fr) Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
BR9602664A (pt) Recipiente oco de plástico tendo um acabamento com um diâmetro menor de que o corpo do recipiente
DK601188D0 (da) Flerfarvet sammensaetning til murbeklaedning
BR9812430A (pt) Dispositivo aplicador
AU4539896A (en) Composition capable of releasing acraldehyde and its use

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed